Dupilumab may break the “itch‐scratch cycle” in chronic prurigo and induce remission in a subset of patients.

A study published in the Journal of the European Academy of Dermatology & Venereology explores the use of dupilumab in the treatment of chronic prurigo (CPG), a condition characterized by chronic itching and pruriginous lesions. The study reports on a series of CPG patients treated with dupilumab, with a focus on three patients who achieved complete disease control even after discontinuing the drug. The study suggests that dupilumab may break the "itch-scratch cycle" and induce disease remission in a subset of patients. Further research is needed to confirm these findings and identify the specific characteristics of patients who may benefit from dupilumab treatment. [Extracted from the article]